Effect of the New Antiepileptic Drug Levetiracetam in an Animal Model of Mania

Epilepsy and Behavior

Volumn 2, Issue 5, 2001, Pages 454-459

  Lamberty, Yves ^a   Margineanu, Doru Georg ^a   Klitgaard, Henrik ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Animal model of mania; Antiepileptic drugs; Bipolar disorder; Carbamazepine; Levetiracetam; Lithium; Rat; Valproate; Y maze

Indexed keywords

EID: 0038285713     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1006/ebeh.2001.0254     Document Type: Article

References (28)

1. Post R M, Weiss S R, Chuang D M. Mechanism of anticonvulsants in affective disorders: comparison with lithium. J Clin Psychopharmacol. 12:1992;S23-35.
2. Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry. 12:2000;5-10.
3. Cabras P L, Hardoy M J, Hardoy M C, Carta M G. Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study. J Clin Psychiatry. 60:1999;245-248.
4. Chengappa K N, Rathore D, Levine J. Topiramate as add-on treatment for patients with bipolar mania. Bipol Disord. 1:1999;42-53.
5. Kaufman K R. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann Clin Psychiatry. 10:1998;181-184.
6. Dubovsky S L, Franks R D. Intracellular calcium ions in affective disorders: a review and a hypothesis. Biol Psychiatry. 18:1983;781-797.
7. Walden J, Grunze H, Bingmann D, Liu Z, Dusing R. Calcium antagonistic effects of carbamazepine as a mechanism of action in neuropsychiatric disorders: studies in calcium dependent model epilepsies. Eur Neuropsychopharmacol. 2:1992;455-462.
8. Taylor C P, Narasimhan L S. Sodium channels and therapy of the central nervous system diseases. Adv Pharmacol. 39:1997;47-98.
9. Xie X, Hagan R M. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology. 38:1998;119-130.
10. Klitgaard H, Matagne A, Gobert J, Wulfert E. Evidence for a unique preclinical profile of levetiracetam in rodents models of seizure and epilepsy. Eur J Pharmacol. 353:1998;191-206.
11. 2+ currents. Seizure. 10:2001;279-286.
12. Sills G J, Leach J P, Fraser C M, Forest G, Patsalos P N, Brodie M J. Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. Eur J Pharmacol. 325:1997;35-40.
13. Löscher W, Hönack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther. 284:1998;474-479.
14. Post R M, Altshuler L L, Ketter T A, Denicoff K, Weiss S RB. Antiepileptic drugs in affective illness: clinical and theoretical implications. Adv Neurol. 55:1991;239-277.
15. Post R M, Weiss S RB. Kindling and manic-depressive illness. Bolwig T G, Trimble M R. The clinical relevance of kindling. 1989;Wiley, New York.
16. Margineanu D G, Wulfert E. Inhibition by levetiracetam of a non-GABAA receptor-associated epileptiform effect of bicuculline in rat hippocampus. Br J Pharmacol. 122:1997;1146-1150.
17. Birnstiel S, Wulfert E, Beck S G. Levetiracetam (ucb L059) effects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission. Naunyn Schmiedebergs Arch Pharmacol. 356:1997;611-618.
18. Wulfert E, Margineanu D G. Thapsigargin inhibits bicuculline-induced epileptiform excitability in rat hippocampal slices. Neurosci Lett. 243:1998;141-143.
19. 2+ current in pyramidal neurons of rat hippocampal slices. Neurosci. Letters. 306:2001;5-8.
20. Margineanu D G, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic. Pharmacol Res. 42:2000;281-285.
21. Robbins T W, Sahakian B J. Animal models of mania. Belmaker R, Van Praag H. Mania: an evolving concept. 1980;Spectrum, New York.
22. Lyon M. Animal models of mania and schizophrenia. Willner P. Behavioural models in psychopharmacology. 1991;Cambridge Univ Press, New York/London.
23. Cox C, Harrison-Read P E, Steinber H, Tomkiewicz M. Lithium attenuates drug-induced hyperactivity in rats. Nature. 232:1971;336-337.
24. Vale A L, Ratcliffe F. Effect of lithium administration on rat brain 5-hydroxyindole levels in a possible animal model of mania. Psychopharmacology. 91:1987;352-355.
25. Cao B J, Peng N A. Magnesium valproate attenuates hyperactivity induced by dexamphetamine-chlordiazepoxide mixture in rodents. Eur J Pharmacol. 237:1993;177-181.
26. Gower A J, Noyer M, Verloes R, Gobert J, Wulfert E. ucb L059, a novel anticonvulsant drug: pharmacological profile in animals. Eur J Pharmacol. 222:1992;193-203.
27. Lamberty Y, Margineanu D G, Klitgaard H. Absence of negative impact of levetiracetam on cognitive function and memory in normal and amygdala-kindled rats. Epilepsy Behav. 1:2000;333-342.
28. Noyer M, Gillard M, Matagne A, Hénichart J P, Wulfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol. 286:1995;137-146.